IE
CAPR icon

Israel Englander’s Capricor Therapeutics CAPR Stock Holding History

Israel Englander’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
+43,300
New +$1.31M ﹤0.01% 4285
2025
Q3 		– Sell
-12,500
Closed -$124K – 6059
2025
Q2 		$124K Buy
+12,500
New +$132K ﹤0.01% 5482
2024
Q4 		– Sell
-15,500
Closed -$236K – 5984
2024
Q3 		$236K Buy
+15,500
New +$76.7K ﹤0.01% 5345

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Israel Englander's CAPR Position: Q2 2026 in Review

Israel Englander reduced its Capricor Therapeutics (CAPR) stake by 34% in Q2 2026, selling an estimated $3.71M and leaving 233,926 shares worth $5.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2879.

Israel Englander first reported a position in CAPR in Q1 2015 and has held it in 23 quarters since. The position peaked at $19.7M in Q4 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Israel Englander held 233,926 shares of Capricor Therapeutics worth $5.63M as of Q2 2026.
  • Israel Englander sold 122,428 Capricor Therapeutics shares in Q2 2026, an estimated $3.71M.
  • Capricor Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2879 holding.
  • Israel Englander first reported a position in Capricor Therapeutics in Q1 2015 and has held it in 23 quarters since.
  • Israel Englander's Capricor Therapeutics position peaked at $19.7M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.